Topics
Ependymal tumors | Treatment | Targeted therapy | Bevacizumab
Home > Publications > Topics > Ependymal tumors > Treatment > Targeted therapy > Bevacizumab
Zhang S, Ozer BH, Omuro A, Yuan Y, Mendoza T, Wall K, Grajkowska
E, Vera E, Reyes J, Aldape K, Penas-Prado M, Wu J, Burton EC,
Walbert T, Mikkelsen T, Weathers SP, O'Brien B, de Groot J,
Puduvalli V, DeAngelis L, Pentsova E, Kaley TJ, Gavrilovic I,
Gerstner ER, Armstrong TS, Gilbert MR.
CERN
09-02: A phase 2 trial of carboplatin and bevacizumab for
recurrent adult ependymomas.
Neurooncol
Adv. 2026 Mar 9;8(1):vdag016. doi:
10.1093/noajnl/vdag016. PMID:
42016022. Trial
registration ID: NCT01295944.
ˍ